The University of Exeter, UK, has launched the world’s first post-graduate course on psychedelics.
Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.
Mind Medicine has confirmed it has completed enrollment of Study MMED007, its Phase 2a study evaluating repeated low-dose administration of MM-120 (LSD) for the treatment of...
Beckley Psytech has confirmed it has dosed the first patient in its international Phase 2b study of BPL-003 – a novel synthetic intranasal formulation of 5-MeO-DMT...
The Brain & Behavior Research Foundation has announced it is awarding $10.2 million in Young Investigator Grants including for projects investigating psychedelics.
Multiple studies have shown that ketamine is a fast acting treatment for depression, but a key issue with the studies is that many participants can tell...
Following all the hype generated about the therapeutic powers of psychedelics by Michael Pollan’s 2018 book How to Change Your Mind and follow up 2022 Netflix...
Diamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization.
A new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and...
Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
